J
Jürgen Braun
Researcher at Humboldt University of Berlin
Publications - 398
Citations - 21254
Jürgen Braun is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Magnetic resonance elastography & Ankylosing spondylitis. The author has an hindex of 79, co-authored 365 publications receiving 18936 citations. Previous affiliations of Jürgen Braun include Free University of Berlin & Charité.
Papers
More filters
Journal ArticleDOI
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten,Xenofon Baraliakos,Jürgen Braun,Joachim Sieper,Paul Emery,Désirée van der Heijde,Iain B. McInnes,Jacob M van Laar,Robert Landewé,Paul Wordsworth,Paul Wordsworth,Jürgen Wollenhaupt,Herbert Kellner,Jacqueline E Paramarta,Jiawei Wei,Arndt Brachat,Stephan Bek,Didier Laurent,Yali Li,Ying A Wang,Arthur P. Bertolino,Sandro Gsteiger,Andrew M Wright,Wolfgang Hueber +23 more
TL;DR: Secukinumab rapidly reduced clinical or biological signs of active ankylosing spondylitis and was well tolerated, making it the first targeted therapy that is an alternative to tumour necrosis factor inhibition to reach its primary endpoint in a phase 2 trial.
Journal ArticleDOI
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park,Paweł Hrycaj,Sławomir Jeka,Volodymyr Kovalenko,Grygorii Lysenko,Pedro Miranda,Helena Mikazane,Sergio Gutierrez-Ureña,Mie Jin Lim,Yeon Ah Lee,Sang Joon Lee,Ho Ung Kim,Dae Hyun Yoo,Jürgen Braun +13 more
TL;DR: CT-P 13 was well tolerated, with an efficacy and safety profile comparable to that of INX up to week 30, and the PK profiles of CT-P13 and INX were equivalent in patients with active ankylosing spondylitis.
Journal ArticleDOI
Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria.
TL;DR: A new set of criteria for IBP performed better than previous criteria in AS patients with established disease and a prospective study is needed to validate the diagnostic properties of the new candidate criteria set in patients with early disease.
Journal ArticleDOI
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
Josef S Smolen,Jürgen Braun,Maxime Dougados,Paul Emery,Oliver FitzGerald,Philip S. Helliwell,Arthur Kavanaugh,Tore K Kvien,Robert Landewé,Thomas A. Luger,Philip J. Mease,Ignazio Olivieri,John D. Reveille,Christopher T. Ritchlin,Martin Rudwaleit,Monika Schoels,Joachim Sieper,Martinus de Wit,Xenofon Baraliakos,Neil Betteridge,Ruben Burgos-Vargas,Eduardo Collantes-Estevez,Atul Deodhar,Dirk Elewaut,Laure Gossec,Merryn Jongkees,Mara Maccarone,Kurt Redlich,Filip Van den Bosch,James Cheng-Chung Wei,Kevin L. Winthrop,Désirée van der Heijde +31 more
TL;DR: The task force defined the treatment target for SpA as remission or, alternatively, low disease activity, being aware that the evidence base is not strong and needs to be expanded by future research.
Journal ArticleDOI
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis
TL;DR: A shorter disease duration, younger age, and a lower BASFI are predictors of a major clinical response to TNF blockers in active AS, while raised CRP and a higher BASDAI may also be valuable predictors.